Canaccord Genuity Group (TSE:CF – Free Report) had its price target raised by TD Securities from C$10.00 to C$12.00 in a ...

On Wednesday, Blend Labs Inc (BLND) stock saw a decline, ending the day at $4.36 which represents a decrease of $-0.19 or -4.18% from the prior close of $4.55. The stock opened at $4.59 and touched a ...

Canaccord Genuity Group (TSE:CF – Free Report) had its target price lifted by Cormark from C$11.50 to C$12.50 in a report issued on Tuesday,BayStreet.CA reports. Cormark also issued estimates for ...

Fintel reports that on November 13, 2024, Canaccord Genuity downgraded their outlook for Doximity (NYSE:DOCS) from Buy to ...

Fintel reports that on November 13, 2024, Canaccord Genuity upgraded their outlook for Viant Technology (NasdaqGS:DSP) from ...

Canaccord Genuity on Wednesday downgraded Doximity (NYSE:DOCS) to hold from buy, noting that its shares, after a more than 30% rally following the company’s Q2 results, already reflect high ...

ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness ...

Canaccord Genuity Group Inc. recorded strong growth in wealth-management and capital-markets divisions for its fiscal second ...

Firm-wide Revenue: $128 million for the quarter, up 27% year-over-year. Fiscal Year-to-Date Revenue: $857 million, up 26% ...

Analysts at Canaccord Genuity lowered their target price on shipbroking services business Braemar from 410.0p to 380.0p on ...

Canaccord Genuity Group Inc (TSX:CF) is set to release its Q2 2025 earnings on Nov 7, 2024. The consensus estimate for Q2 2025 revenue is $0.43 million, and the earnings are expected to come in at $0.

About Elutia Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of ...